Why ImmunityBio Stock Is Soaring Again Today
Key Points
ImmunityBio's sales grew 700% in 2025, with fourth-quarter revenue rising 20% quarter over quarter.
These excellent results extend an incredible run of good news for the up-and-coming biotech stock.
While it offers immense potential, ImmunityBio is now worth $10 billion, and will undoubtedly be a volatile ride for investors.
- 10 stocks we like better than ImmunityBio ›
Shares of cancer immunotherapy specialist ImmunityBio (NASDAQ: IBRX) are up 16% as of noon ET on Monday after the company reported fourth-quarter earnings. The company's leading immunotherapy (and main sales generator), Anktiva, grew sales by 700% in 2025, and delivered 20% quarter-over-quarter growth in Q4. While earnings per share remained negative at $0.06 in Q4, it was the third straight quarter of profitability improvement as Anktiva rapidly expands. Following today's rise on ImmunityBio's solid earnings, the stock has already roughly quintupled in 2026 as it continues to reel off positive news.
ImmunityBio's incredible 2026
Through its Cancer BioShield platform and Anktiva biologic product, ImmunityBio stimulates natural killer cells, cytotoxic T cells, and memory T cells, helping patients fight a growing number of cancers and diseases. While the bulk of ImmunityBio's business currently comes from U.S. sales of Anktiva, a treatment for bladder cancer cases that did not respond to the Bacille Calmette-Guérin (BCG) vaccine, the company is rapidly expanding.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
So far in 2026, ImmunityBio:
- launched Anktiva in Saudi Arabia to treat bladder cancer and lung cancer, demonstrating success with a new indication
- opened an Irish subsidiary to support launching Anktiva across 33 countries in Europe, after receiving approval from the European Commission for BCG-unresponsive bladder cancer
- delivered excellent efficacy and safety results for a non-Hodgkin lymphoma (NHL) clinical study, further expanding the company's reach
- continues clinical trials for glioblastoma, sepsis, NHL, and the treatment of lymphopenia
Ultimately, things look great for ImmunityBio right now. Its main indication is seeing stellar growth, the company is diversifying quickly across new use cases and geographies, and its pipeline looks promising. That said, investors need to keep in mind that ImmunityBio has a $10 billion market cap and has yet to generate tangible profits due to its young age, so it will likely remain a volatile ride for investors. This investment is outside my risk tolerance, but if biotech-savvy investors really like ImmunityBio's promise, I'd only recommend making tiny purchases over time rather than a sizable investment in the nascent growth stock at once -- especially after this run.
Should you buy stock in ImmunityBio right now?
Before you buy stock in ImmunityBio, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and ImmunityBio wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 23, 2026.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
